Democratizing hedge fund level analysis tools for everyone
| Name | Indofarma Tbk. |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Health Care Research |
| Code | F2 |
| Latest Quarterly | 06-30-25 |
| Name | Latest % | A Month Ago % |
|---|---|---|
| PT. Bio Farma (Persero) | 80.66 | 80.66 |
| Public < 5% | 11.99 | 11.99 |
| PT. Asabri (Persero) - Dapen Tni | 7.34 | 7.34 |
| Source | 2022 | 2021 |
|---|---|---|
| INAF | F2 | Medicine |
| INAF | F2 | Medical Devices & Others |
| INAF | F2 | Others |
| INAF | F2 | Engineering Pharmaceutical |
| Region | 2022 | 2021 |
|---|---|---|
| INAF | F2 | Indonesia |
| INAF | F2 | Others |
| Valuation | Ratio | Rank |
|---|---|---|
| P/S | 2.19 | # 13 / 15 |
| EV_EBITDA | -12.87 | --- / 15 |
| PER | -2.30 | --- / 15 |
| PBV | -0.42 | --- / 15 |
| DER | -1.65 | --- / 15 |
| Profitability | Ratio | Rank |
|---|---|---|
| NPM % | -95.031 | --- / 15 |
| ROA % | -29.14 | --- / 15 |
| ROE % | 18.360000000000003 | # 4 / 15 |
| Year | DPS | Yield [%] |
|---|
| Timeframe | Performance |
|---|---|
| 1W % | -3.1 |
| 1Mo % | -45.2 |
| 3Mo % | -68.8 |
| 1Yr % | -79.7 |
| Stocks | PER | Market Cap | EV | Revenue | EBITDA | Net Profit |
|---|---|---|---|---|---|---|
| KLBF | 16.21 | 56.88 T | 58.14 T | 34,651 B | 5,348 B | 3,508 B |
| SOHO | 30.18 | 17.51 T | 19.64 T | 10,338 B | 711 B | 581 B |
| SIDO | 14.84 | 16.20 T | 15.77 T | 3,639 B | 1,481 B | 1,091 B |
| TSPC | 8.20 | 12.45 T | 10.93 T | 13,512 B | 2,016 B | 1,515 B |
| PYFA | -11.02 | 5.39 T | 11.42 T | 2,747 B | -142 B | -488 B |
| MDLA | 9.50 | 3.67 T | 6.27 T | 14,788 B | 557 B | 386 B |